YouTube video by Rob Scallon

Cardiol Therapeutics (NASDAQ: CRDL) entered a bought deal private placement to issue 10,384,616 units at $1.30 per unit for gross proceeds of $13.5 million, with an underwriter option to sell up to an additional 1,038,462 units to raise up to $1.35 million. Each unit includes one common share and one-half warrant; each full warrant exercisable at $1.75 for 24 months.The offering is expected to close on or about January 23, 2026, is subject to TSX approvals and customary conditions, and the company intends to use net proceeds to advance research and clinical development and for general corporate purposes.

Clinical trial infrastructure fully operational in the U.S. with more than 15 leading cardiovascular centers actively enrolling patients. Activation of additional top-tier clinical sites in Europe and Canada underway, further accelerating enrollment momentum. Full enrollment expected in Q2 2026.

YouTube video by SMITHWEEKLY RESEARCH

Leede Financial analyst Douglas Loe has cut his target on Cardiol Therapeutics

Cardiol (NASDAQ: CRDL) receives U.S. patent allowance for CardiolRx, CRD-38 to 2040  Stock Titan

Cardiol Therapeutics (NASDAQ: CRDL) received a U.S. Notice of Allowance for a patent titled "Cannabidiol Compositions for Use in Treating Heart Conditions", which upon issuance will protect use of CardiolRx and CRD-38 for a broad range of cardiac disorders through October 2040.The allowance expands the company's global IP portfolio alongside granted and pending patents in Europe, Japan, Canada, Australia, and China, and complements its U.S. Orphan Drug Designation for pericarditis. Management said the allowance supports late-stage programs in recurrent pericarditis and acute myocarditis and upcoming first-in-human evaluation of CRD-38. The company plans to present ARCHER topline data on November 29, 2025, and will update on Phase III MAVERIC enrollment progress.

Cardiol Therapeutics (NASDAQ: CRDL) announced that full Phase II ARCHER trial data for CardiolRx will be presented on November 29, 2025 at the ESC Working Group on Myocardial & Pericardial Disease meeting in Trieste, Italy. Topline results reported improvements in extracellular volume and a significant reduction in left ventricular mass after twelve weeks of blinded therapy in acute myocarditis patients with preserved LV function.The randomized, double-blind, placebo-controlled ARCHER trial enrolled 109 patients across the US, France, Brazil, and Israel. Cardiol will host a webcast and conference call on December 1, 2025 to discuss findings and next steps.

Cardiol Therapeutics (NASDAQ: CRDL) completed a private placement of 11.4 million units for US$11.4 million on October 21, 2025, funding operations into Q3 2027. Each unit = one common share plus one-half warrant; whole warrants exercise at US$1.35 for 24 months with an acceleration clause if VWAP > US$2.00 for five consecutive trading days. Proceeds fully fund the pivotal MAVERIC Phase III trial and advance CRD-38 through clinical development. New ARCHER trial data showing meaningful LV mass reduction will be presented at a November 2025 cardiology conference. Certain insiders participated under MI 61-101 exemptions.

MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA. New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read through

YouTube video by Orgaysis